| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $265.6M | +92.9% |
| SG&A Expense | $35.2M | +71.7% |
| Operating Income | -$300.8M | -90.1% |
| Income Tax | $0 | — |
| Net Income | -$294.2M | -89.8% |
| EPS (Basic) | -$10.38 | +85.6% |
| EPS (Diluted) | -$10.38 | +85.6% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $169.5M | +268.6% |
| Short-term Investments | $118.7M | +3916.8% |
| Current Assets | $306.2M | +473.8% |
| Total Assets | $341.0M | +280.5% |
| Current Liabilities | $50.9M | +143.9% |
| Total Liabilities | $80.9M | +51.2% |
| Stockholders' Equity | $260.1M | +176.7% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$255.1M | -96.3% |
| Capital Expenditures | $1.7M | -61.5% |
| Investing Cash Flow | -$113.8M | -288.2% |
| Financing Cash Flow | $492.4M | +449.0% |
| Free Cash Flow | -$256.8M | -91.0% |